IL15 and cancer: This later is frequently downregulated in cancer patients, reducing the efficacy of IL-15-based treatments, hence the development of other strategies such as IL-15 superagonist receptor-linker–IL-15 (RLI), designed to bypass the need for endogenous IL-15RA, as a promising approach to stimulate host immunity (44).